• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌根治术后前列腺特异性抗原升高患者中放射性核素骨扫描的作用有限。

Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy.

作者信息

Cher M L, Bianco F J, Lam J S, Davis L P, Grignon D J, Sakr W A, Banerjee M, Pontes J E, Wood D P

机构信息

Department of Urology, Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, Michigan, USA.

出版信息

J Urol. 1998 Oct;160(4):1387-91.

PMID:9751361
Abstract

PURPOSE

Bone scintigrams of patients with increasing serum prostate specific antigen (PSA) after radical prostatectomy are only rarely positive. We identify clinical parameters that would improve our ability to select patients for this imaging study.

MATERIALS AND METHODS

We reviewed all bone scintigrams done at our institution between 1991 and 1996 in patients with persistently increasing serum PSA after radical prostatectomy. What prompted the clinician to obtain the bone scintigram was trigger PSA (tPSA). The rate of increase in PSA to tPSA was measured by tPSA/time from radical prostatectomy (slope 1) and tPSA/time from last undetectable PSA (slope 2). These parameters were evaluated together with standard clinicopathological data in univariate and multivariate analyses to determine the ability to predict the bone scintigram result.

RESULTS

In univariate analysis tPSA (p = 0.003), slope 1 (p = 0.005) and slope 2 (p = 0.004) were useful in predicting the bone scintigram result but pathological stage, Gleason score, preoperative PSA and time to recurrence were not. In multivariate analysis the single most useful parameter in predicting the bone scintigram result was tPSA (p = 0.01). Based on a logistic regression model the probability of a positive bone scintigram was less than 5% until tPSA increased to 40 to 45 ng./ml.

CONCLUSIONS

In patients with increasing serum PSA after radical prostatectomy current serum PSA is the best predictor of the bone scintigram result. Furthermore, there is limited usefulness of bone scintigraphy until PSA increases above 30 to 40 ng./ml.

摘要

目的

根治性前列腺切除术后血清前列腺特异性抗原(PSA)持续升高的患者,其骨闪烁扫描结果很少为阳性。我们旨在确定能提高选择患者进行此项影像学检查能力的临床参数。

材料与方法

我们回顾了1991年至1996年间在本机构对根治性前列腺切除术后血清PSA持续升高患者所做的所有骨闪烁扫描。促使临床医生进行骨闪烁扫描的是触发PSA(tPSA)。PSA升至tPSA的速率通过从根治性前列腺切除术开始计算的tPSA/时间(斜率1)以及从上次不可检测的PSA开始计算的tPSA/时间(斜率2)来衡量。在单因素和多因素分析中,将这些参数与标准临床病理数据一起评估,以确定预测骨闪烁扫描结果的能力。

结果

在单因素分析中,tPSA(p = 0.003)、斜率1(p = 0.005)和斜率2(p = 0.004)在预测骨闪烁扫描结果方面有用,但病理分期、Gleason评分、术前PSA和复发时间则不然。在多因素分析中,预测骨闪烁扫描结果最有用的单一参数是tPSA(p = 0.01)。基于逻辑回归模型,在tPSA升至40至45 ng/ml之前,骨闪烁扫描阳性的概率小于5%。

结论

根治性前列腺切除术后血清PSA升高的患者,当前血清PSA是骨闪烁扫描结果的最佳预测指标。此外,在PSA升高至30至40 ng/ml以上之前,骨闪烁扫描的作用有限。

相似文献

1
Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy.前列腺癌根治术后前列腺特异性抗原升高患者中放射性核素骨扫描的作用有限。
J Urol. 1998 Oct;160(4):1387-91.
2
Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?前列腺癌根治术后生化复发患者的放射性核素骨闪烁显像:何时进行该项检查?
BJU Int. 2004 Aug;94(3):299-302. doi: 10.1111/j.1464-410X.2004.04927.x.
3
[Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].[前列腺特异性抗原和Gleason评分对前列腺癌患者放射性核素骨显像结果的预测价值]
Beijing Da Xue Xue Bao Yi Xue Ban. 2012 Aug 18;44(4):528-34.
4
Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.根治性前列腺切除术前行生化复发风险评估:血清前列腺特异抗原(PSA)中度升高男性中,人组织激肽释放酶2(hK2)和游离前列腺特异抗原(PSA)对显著增强风险评估有重要作用。
Int J Cancer. 2006 Mar 1;118(5):1234-40. doi: 10.1002/ijc.21474.
5
How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure.
Semin Urol Oncol. 1999 Aug;17(3):130-4.
6
Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.使用基于前列腺特异性抗原密度和活检Gleason评分的新型风险分组系统改善根治性前列腺切除术后生化复发的风险分层。
J Urol. 2002 Jul;168(1):110-5.
7
Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.骨闪烁扫描和计算机断层扫描在评估前列腺癌根治术后生化复发方面价值有限。
Urology. 2003 Mar;61(3):607-11. doi: 10.1016/s0090-4295(02)02411-1.
8
Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.通过超敏检测法测得的血清前列腺特异性抗原最低点值作为临床局限性前列腺癌根治性前列腺切除术后生化复发预测指标的实用性。
Urol Int. 2006;76(3):227-31. doi: 10.1159/000091624.
9
Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy.血清总前列腺特异抗原(tPSA)、复合前列腺特异抗原(cPSA)、相关密度参数及嗜铬粒蛋白A作为根治性前列腺切除术后切缘阳性的预测指标。
Anticancer Res. 2007 Jul-Aug;27(4C):2817-21.
10
Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.临床局限性前列腺癌单纯根治性前列腺切除术后临床及病理因素与前列腺特异性抗原水平升高的相关性
Urology. 1996 Aug;48(2):249-60. doi: 10.1016/S0090-4295(96)00167-7.

引用本文的文献

1
Whole-Body Bone Scan for Detecting Bone Metastasis in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era: A Retrospective Cohort Study of Post-Radical Prostatectomy Prostate Cancer Patients.在前列腺特异性膜抗原正电子发射断层扫描时代,全身骨扫描用于检测前列腺癌根治术后患者的骨转移:一项回顾性队列研究
Asia Ocean J Nucl Med Biol. 2025;13(2):146-155. doi: 10.22038/aojnmb.2025.82544.1582.
2
[Opportunities for prostate-specific membrane antigen hybrid imaging in prostate cancer].[前列腺特异性膜抗原杂交成像在前列腺癌中的应用机会]
Urologie. 2023 Nov;62(11):1153-1159. doi: 10.1007/s00120-023-02189-z. Epub 2023 Sep 13.
3
Salvage therapy for prostate cancer after radical prostatectomy.
根治性前列腺切除术后的前列腺癌挽救治疗。
Nat Rev Urol. 2021 Nov;18(11):643-668. doi: 10.1038/s41585-021-00497-7. Epub 2021 Aug 6.
4
[F]DCFPyL PET/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA < 0.5 ng/mL.[F]DCFPyL PET/CT 在前列腺切除术后 PSA<0.5ng/mL 以下的复发性前列腺癌的检测和定位中的应用。
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):2038-2046. doi: 10.1007/s00259-020-05143-9. Epub 2021 Jan 5.
5
Monitoring Therapy Efficiency in Cancer through Extracellular Vesicles.通过细胞外囊泡监测癌症的治疗效率。
Cells. 2020 Jan 6;9(1):130. doi: 10.3390/cells9010130.
6
Biochemical Recurrence in Prostate Cancer and Temporal Association to Bone Metastasis.前列腺癌的生化复发及其与骨转移的时间关联。
Am J Case Rep. 2019 Oct 16;20:1521-1525. doi: 10.12659/AJCR.918569.
7
Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients.镓-68前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描成像在评估前列腺癌患者生化复发中的初步经验。
World J Nucl Med. 2019 Jul-Sep;18(3):244-250. doi: 10.4103/wjnm.WJNM_47_18.
8
Contribution of Radiology to Staging of Prostate Cancer.放射学在前列腺癌分期中的作用。
Semin Nucl Med. 2019 Jul;49(4):294-301. doi: 10.1053/j.semnuclmed.2019.02.007. Epub 2019 Mar 9.
9
Novel Imaging in Detection of Metastatic Prostate Cancer.新型影像学在转移性前列腺癌检测中的应用。
Curr Oncol Rep. 2019 Mar 5;21(4):31. doi: 10.1007/s11912-019-0780-8.
10
Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies.前列腺癌根治术后的生化复发:作为治疗终点的应用现状及早期管理策略
Indian J Urol. 2019 Jan-Mar;35(1):6-17. doi: 10.4103/iju.IJU_355_18.